Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab - PubMed
6 hours ago
- #second-line therapy
- #advanced urothelial carcinoma
- #real-world outcomes
- The study evaluated treatment patterns and outcomes of second-line therapies for advanced urothelial carcinoma patients who progressed after first-line enfortumab vedotin with pembrolizumab.
- Among 118 patients analyzed, second-line treatments included carboplatin-based (35%), cisplatin-based (13%), EV rechallenge (13%), and other regimens (38%).
- The 'Other' category comprised erdafitinib, trastuzumab deruxtecan, and sacituzumab govitecan.
- Real-world time to next therapy (rwTTNT) ranged from 3-4.7 months for platinum regimens to 8.5 months with EV rechallenge.
- Real-world overall survival (rwOS) was 7.1-8.5 months for platinum-based therapy or EV rechallenge, and 14 months for other regimens.
- Findings indicate limited efficacy of current second-line options post EV + pembro, with modest rwOS and rwTTNT across all groups.